- January 2025: Started at approximately $35.57, then began a concerning decline
- February-March: Continued downward pressure, dropping to the $26-30 range
- April-May: Reached concerning lows around $16-17, testing investor patience
- June-July: Remarkable turnaround with +2.24% and +12.48% monthly gains respectively
- August 2025: Continued recovery, reaching current levels around $28
How to Buy Apellis Pharmaceuticals, Inc. (APLS) Shares - Investment in APellis Pharmaceuticals, Inc. (APLS) Stock
Updated on 24 Aug 2025
Thinking about investing in a company that's revolutionizing eye disease treatment? Apellis Pharmaceuticals represents the exciting intersection of medical innovation and investment opportunity. With their groundbreaking SYFOVRE treatment for geographic atrophy and recent FDA approvals, this biotech firm offers both scientific promise and financial potential. Let's explore what makes APLS stock worth your attention.
Article navigation
- Current Market Position and Entry Point
- Six-Month Price Journey: From Struggle to Strength
- Price Forecast: 2025-2030 Outlook
- Risk Assessment vs. Positive Signals
- Recent News Impact Analysis
- Step-by-Step: How to Buy Apellis Pharmaceuticals, Inc. (APLS) Shares
- Smart Strategy for Beginners
- Why Pocket Option Fits New Investors
- Company Overview: Apellis in 2025
Current Market Position and Entry Point
As of August 24, 2025, Apellis Pharmaceuticals (APLS) trades at $27.97 per share. This price represents a crucial juncture for investors considering how to buy Apellis Pharmaceuticals, Inc. (APLS) shares, as the stock has shown remarkable recovery momentum in recent months.
Critical Date Alert: Mark November 4, 2025 on your calendar. This is when Apellis releases their Q3 earnings report. Historical patterns show these events significantly impact APLS stock price movement.
Earnings Impact Analysis:
Looking at recent quarterly reports, Apellis stock typically experiences 5-15% price swings around earnings announcements. The Q2 2025 report on July 31st showed mixed results – revenue missed expectations but earnings per share beat estimates by 25%. This pattern suggests careful analysis of both top-line and bottom-line performance is essential when considering investment in Apellis Pharmaceuticals, Inc. (APLS) stock.
Six-Month Price Journey: From Struggle to Strength
Apellis shares have navigated a dramatic transformation over the past six months:
This represents a classic biotech volatility pattern – sharp declines followed by explosive recoveries. For those learning how to buy Apellis Pharmaceuticals, Inc. (APLS) shares, this history demonstrates both the risks and opportunities in pharmaceutical investing.
Price Forecast: 2025-2030 Outlook
Based on current analyst consensus and company developments, here’s what to expect:
- 2025 Year-End: $30-34 range (moderate growth from current levels)
- 2026 Projection: $28-32 (consolidation phase expected)
- 2028 Outlook: $48-52 (significant growth potential from pipeline expansion)
- 2030 Vision: $50-55+ (long-term value creation from market leadership)
Verdict: BUY for long-term investors. The recent FDA approval for EMPAVELI and strong SYFOVRE performance create fundamental strength that supports future growth.
Risk Assessment vs. Positive Signals
⚠️ Key Risks to Consider:
- Regulatory uncertainty: FDA decisions can make or break biotech stocks
- Competition intensifying: Other companies developing similar treatments
- Cash burn concerns: Despite $370M cash position, R&D costs remain high
- Market volatility: Biotech stocks typically show higher beta than market average
✅ Positive Signals for 2025:
- FDA approval success: EMPAVELI approved for C3G/IC-MPGN (Q2 Earnings Report)
- Revenue growth: SYFOVRE delivered $151M in Q2 revenue, up 6% quarterly
- Strategic partnerships: $300M royalty deal with Sobi provides financial stability
- Market leadership: SYFOVRE captures >60% new patient share in geographic atrophy
Recent News Impact Analysis
Apellis has been making waves in 2025 with several significant developments:
- Q2 Earnings Performance: While revenue of $178M missed expectations, the EPS beat by 25% shows improving operational efficiency (AInvest Analysis)
- FDA Expansion: The approval of EMPAVELI for additional conditions opens a potential $500M per patient market opportunity (Market Analysis)
- Institutional Confidence: Fox Run Management’s new investment in August 2025 signals continued professional interest (Institutional Filing)
Step-by-Step: How to Buy Apellis Pharmaceuticals, Inc. (APLS) Shares
| Step | Action | Why It Matters |
|---|---|---|
| 1 | Choose a trading platform | Ensure it offers NASDAQ access for US stocks |
| 2 | Complete account verification | Most platforms require ID and address confirmation |
| 3 | Deposit funds | Start with an amount you’re comfortable risking |
| 4 | Research current APLS price | Check real-time quotes before ordering |
| 5 | Place your order | Use limit orders to control entry price |
| 6 | Monitor your investment | Set price alerts for important levels |
| 7 | Consider dollar-cost averaging | Spread purchases over time to reduce timing risk |
Smart Strategy for Beginners
For those new to how to buy Apellis Pharmaceuticals, Inc. (APLS) shares, here’s my professional advice:
- Start small – Biotech stocks can be volatile; begin with a position size that won’t keep you up at night
- Focus on long-term – Pharmaceutical development takes years; think in terms of 3-5 year horizons
- Diversify appropriately – Don’t put all your eggs in one biotech basket
- Set stop-losses – Protect your capital from unexpected downturns
And my humorous take: “Trading APLS is like watching medical research – sometimes you need strong stomach for the clinical trials, but the successful treatments make it worth the wait!”
Why Pocket Option Fits New Investors
For those considering how to buy Apellis Pharmaceuticals, Inc. (APLS) shares, Pocket Option offers several advantages:
- Minimum deposit just $5 – Perfect for testing strategies with minimal risk
- Rapid verification – Start trading quickly with simple document upload
- Multiple withdrawal options – Access your profits through various convenient methods
- User-friendly platform – Designed for beginners while offering advanced features
Company Overview: Apellis in 2025
Apellis Pharmaceuticals stands as a global leader in complement-mediated disease treatment. The company has transitioned from clinical-stage to commercial-stage success with two approved therapies targeting serious conditions.
Their flagship product SYFOVRE treats geographic atrophy, while EMPAVELI addresses multiple rare diseases. With $370 million in cash and growing revenue streams, Apellis demonstrates both scientific innovation and business acumen.
Interesting Fact: In 2025, Apellis achieved something rare in biotech – they successfully expanded their existing drug EMPAVELI to treat completely new conditions (C3G and IC-MPGN), effectively creating new revenue streams without developing entirely new compounds from scratch!
For more educational content on trading strategies and market analysis, visit our Pocket Option blog for regular updates and insights.
FAQ
What is Apellis Pharmaceuticals' main business?
Apellis develops and commercializes therapies for complement-mediated diseases, with focus on innovative C3-targeting treatments.
How often does APLS stock pay dividends?
Apellis does not currently pay dividends as they reinvest profits into research and development.
What was Apellis' revenue in their last quarter?
Q2 2025 revenue was $178 million, with $171 million from U.S. product sales.
Is APLS stock considered high-risk?
Yes, as a clinical-stage biopharmaceutical company, APLS carries higher risk than established pharmaceutical stocks.
Where can I find Apellis' latest financial reports?
All official reports are available on their investor relations website and SEC filings.
Signals
Sign up for more like this
Customize your newsfeed with content you're actually interested in — get up-to-date personalized newsletter in your inbox.
Your comment
Comments are pre-moderated to ensure they comply with our blog guidelines.